AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
A new era, where AI is at the centre of the drug discovery process is emerging, says Charlotte Deane, a professor of ...
The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease ...
This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.
The potential of using artificial intelligence in drug discovery and development has sparked both excitementand skepticism ...
Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...
Among the hundreds of thousands of chemical compounds produced by plants, some may hold the key to treating human ailments and diseases. But recreating these complex, naturally occurring molecules in ...
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback